News

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...
Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 for participating patients. They also more deeply discount the drugs for employers and health plans that contract with ...
Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.
Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...
The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists ...
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...
adding that Evernorth was able to get better pricing while maintaining coverage for both drugs. Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary ...
Evernorth Health Services generated $53.7 billion ... CVS Health and Humana have also joined Wegovy maker Novo Nordisk's NovoCare pharmacy network to provide the GLP-1 through CVS Pharmacy and ...
Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.
The benefit could nudge more Evernorth clients to cover GLP-1s. Currently, only half of its employer clients cover drugs like Wegovy and Zepbound for weight management, executives said on a call ...